Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex

Special Report
March 2021 PBAC outcomes

Posted 26 April 2021 

The PBAC has recommended 23 submissions submitted to its March meeting, although less than a quarter of major new listings requests were included in the recommendations. 

Out of 20 major submissions for new listings (including Gilead's Jyseleca which was withdrawn) only four requests were recommended by the comittee with half of these going to Novartis' drugs.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pharma face-slapped for success
Reputation is finding itself under threat again
Approvals Action
Low dose Symdeko ticked
Along with one generic drug
Special Report
March 2021 PBAC outcomes
Less than a quarter of major new listing requests recommended